<DOC>
	<DOCNO>NCT01160276</DOCNO>
	<brief_summary>Ciclosporin inhibit P-glycoprotein increase colchicine bioavailability whereas tacrolimus influence colchicine disposition . This prospective , control , open label study perform renal graft recipient compare colchicine single dose ( 1mg ) pharmacokinetics 14 patient treat tacrolimus 14 patient treated cyclosporin .</brief_summary>
	<brief_title>Drug Interaction Between Colchicine Calcineurin Inhibitors Renal Graft Recipients</brief_title>
	<detailed_description>- Renal transplantation &gt; = one year - eGFR ( MDRD ) &gt; 30ml/min - hemoglobin &gt; = 11g/dl - treatment tacrolimus cyclosporine - previous muscular disease - drug interfere P-glycoprotein CYP3A activity expression outcomes - colchicine AUC , Cmax , T1/2 - ABCB1C3435T , CYP3A5 SLCO1B1 genotype</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Patients renal graft since least 1 year Patients treat ciclosporin tacrolimus Are least 18 year old . Glomerular filtration rate 30 ml / min calculate use MDRD formula Among 14 patient receive ciclosporin : The genotype criterion inclusion Among 14 patient tacrolimus treatment : 7 genotype ABCB1 3435CC , 7 genotype ABCB1 3435TT Recent ( 1 month ) residual concentration tacrolimus 510ng/ml Recent ( 1 month ) residual concentration ciclosporin 100200ng/ml For woman : negative pregnancy test ( serum beta hCG ) Realization medical examination . Informed consent write form . Abnormal transaminase ( AST ALT ULN Laboratory ) . Underlying Liver Disease ( steatosis , cirrhosis , chronic hepatitis , virus hepatitis C B ) . Previous history muscle disease ( drug relate especially statin type ) . Leukopenia ( WBC &lt; 3000/mm3 ) . Hemoglobin &lt; 11g/dl . Patient treat erythropoetin ( whatever hemoglobin value ) . Abnormal CPK ( great ULN Laboratory ) . Prior intolerance colchicine . Regular intake follow medication associate rhabdomyolyses : antipsychotic , cholesterol lower agent ( statin fibrates ) , zidovudine , antidepressant ( selective inhibitor serotonin reuptake ) lithium . Patient ( e ) refrain consume grapefruit juice . Patient ( e ) take tea base St John 's wort . Taking drug inducer Pgp CYP3A4 ( rifabutin , rifampin , carbamazepine , phenytoin , phenobarbital , efavirenz , nevirapine , protease inhibitor , griseofulvin ) . Taking drug inhibitor Pgp CYP3A4 ( quinidine , macrolide antibiotic , azole antifungal , protease inhibitor , amiodarone , diltiazem , verapamil ) . Chronic diarrhea . ABCB1 Genotype 3435CT patient tacrolimus group . Participation another concurrent trial . Patient ( e ) exclusion period another trial . Patient ( e ) reach maximum annual amount compensation provide law . No affiliation French social security scheme without CMU .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>renal graft</keyword>
	<keyword>colchicine</keyword>
	<keyword>drug interaction</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>renal transplant</keyword>
	<keyword>ABCB1</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>SLCO1B1</keyword>
</DOC>